Introduction {#s1}
============

Renal cell carcinoma (RCC) accounts for approximately 65 000 new cancer cases and 15 000 deaths annually in the USA.[@R1] Sarcomatoid RCC (sRCC) represent a relatively rare subset of cancers of kidney origin with aggressive growth characteristics and pathological similarities to spindle cell sarcomas, including dense cellularity and cellular atypia.[@R2] Approximately 1%--5% of all diagnosed RCCs contain a component of sRCC, which usually becomes the predominant component of tumor during evolution of tumor development.[@R3] Patients with sRCC typically present with metastatic disease at diagnosis.[@R2]

Independent of stage at diagnosis, patients with sRCC have a poorer prognosis than patients with pure clear cell RCC, and current treatment approaches have not yielded significant benefit.[@R3] As with other forms of RCC, chemotherapy regimens such as gemcitabine and doxorubicin are of limited therapeutic utility, with median progression-free survival (PFS) and overall survival (OS) of 3.5 months and 8.8 months, respectively.[@R4] Initial studies involving vascular endothelial growth factor (VEGF) inhibitors have not demonstrated improvement in survival[@R3]; however, a recent phase II study of sunitinib with gemcitabine demonstrated an overall response rate (ORR) of 26% with a stable disease rate of 38%.[@R5]

Several reports have suggested that sRCC tumor cells express programmed cell death ligand 1 (PD-L1) more frequently when compared with clear cell tumors.[@R6] This likely reflects a more inflamed milieu within sRCC, since PD-L1 upregulation is known to result from the presence of type II interferons within the tumor microenvironment.[@R8] Retrospective and prospective data also supports the activity of checkpoint inhibitors in sRCC.[@R9]

An updated analysis of a phase II study of atezolizumab and bevacizumab in patients with clear cell sRCC demonstrated an ORR of 53%.[@R10] In the CheckMate 214 study, an exploratory analysis of a sRCC cohort also demonstrated response to immunotherapy with an ORR of 56.7% with nivolumab plus ipilimumab (95% CI 43.2% to 69.4%) versus 19.2% (95% CI 9.6% to 32.5%) with sunitinib (p\<0.0001).[@R11]

While the data from immunotherapy in sRCC have been encouraging, many patients do not demonstrate a significant response, and responsive patients eventually develop progression. In this case report, we describe a patient with sRCC who had an initial response with ipilimumab and nivolumab, rapid progression on maintenance nivolumab, and subsequent response with rechallenge of ipilimumab. This report also provides a review of relevant literature on the efficacy of ipilimumab in sRCC.

Case report {#s1-1}
-----------

A 46-year-old man presenting with hematuria underwent a diagnostic CT urogram revealing a 14.2×10.6×9.3 cm left renal mass with proximal renal vein thrombosis and retroperitoneal adenopathy. Chest imaging at the time identified small pulmonary nodules which were too small for characterization. The patient underwent a left radical nephrectomy with pathological evaluation identifying a T3N1M0 (14.2×10.6×9.3 cm) renal cell carcinoma with sarcomatoid differentiation (40%).

Two months after nephrectomy, surveillance scans identified extensive presumed metastases in the abdomen, pelvis and both lungs, with the largest mass consisting of a left renal fossa mass measuring 8.9×3.2 cm. Biopsy of a presumed metastatic lesion in left anterior abdominal wall was consistent with poorly differentiated carcinoma with 50%--60% rhabdoid and sarcomatoid differentiation that stained for Pax-8, suggesting metastatic renal cell carcinoma. The patient was considered poor risk as assessed by IInternational Metastatic RCC Database Consortium.

After 3 months on maintenance nivolumab therapy, the size of the patient's retroperitoneal and abdominal wall metastases approximately doubled as assessed by CT scanning of the abdomen and pelvis ([figure 1](#F1){ref-type="fig"}). In consideration of possible subsequent treatments, we noted the patient's prior response to ipilimumab, previous tolerance of combined immunotherapy, good performance status, and sRCC histology which has historically poor outcomes with VEGF inhibitors. Given this information, it was decided to retreat the patient with ipilimumab 1 mg/kg along with continued nivolumab 3 mg/kg every 3 weeks. A partial response was demonstrated on imaging after two additional doses of ipilimumab plus nivolumab, with all but one lesion shrinking by more than 50 per cent (see [figure 2](#F2){ref-type="fig"}, [table 1](#T1){ref-type="table"}). The patient remained on combined immune checkpoint blockade therapy for a total of 9 months with stable disease before treatment was discontinued due to grade 3 fatigue, arthralgias and progression of disease in the right ventricle alone.

![Progression of disease while on nivolumab maintenance therapy only Follow-up CT with contrast after 4 months of nivolumab maintenance therapy only demonstrating marked progression of disease with enlarging left retroperitoneal (red arrows) and abdominal wall (orange arrows) metastases.](jitc-2020-000584f01){#F1}

![Partial Response to therapy after re-challenge of ipilimumab + nivolumab Follow-up CT with contrast after 5 months of nivolumab and re-introduction of ipilimumab demonstrating partial response to therapy with substantially smaller left retroperitoneal (red arrows) and abdominal wall (orange arrows) metastases since previous CT (figure 1). Note the increased low-density central necrosis (\*) in the abdominal wall metastasis indicating treatment response.](jitc-2020-000584f02){#F2}

###### 

Target lesion changes with immunotherapy

  Target lesion      Basal CT in cm   After four cycles IPI+nivo   After four cycles of maintenance nivo   After two doses of IPI and nivo (reintroduction)
  ------------------ ---------------- ---------------------------- --------------------------------------- --------------------------------------------------
  Pre aortic LN      8.9×3.2 cm       3.1×2.6 cm                   4.2×2.4 cm                              2.1×2.5 cm
  Rectus abdominis   5.4×3.6 cm       4.2×3.7 cm                   8.2×7.6 cm                              5.5×7.3 cm (central necrosis present)

IPI, ipilumumab; LN, lymph node.

Discussion {#s2}
==========

sRCC typically portends a poor prognosis as demonstrated by a review of clinical data presented in [table 2](#T2){ref-type="table"}. This may, in part be due to high PD-L1 expression on sRCC cells which has been independently associated with poor outcomes in renal cell cancer.[@R12] In prior studies, BAP1 loss was associated with high tumor grade, sarcomatoid differentiation and poor outcomes, as noted in our patient.[@R13] In RCC, BAP-1 mutations have been identified in approximately 15% of patients with RCC and was noted to enhance mesenchymal--epithelial transition, which could be one reason why our patient presented with metastatic disease within 3 months of diagnosis.[@R15] The Checkmate 214 trial examined the safety and efficacy of anti-PD-1 with anti-CTLA4. A significant improvement in OS was noted in all RCC patients after treatment with ipilimumab and nivolumab compared with sunitinib (median not reached vs 26 months, HR 0.63).[@R17] Among patients with sarcomatoid differentiation, the rate of complete response (CR) was 18.3% with nivolumab plus ipilimumab versus 0% with sunitinib with superior OS in the immunotherapy arm irrespective of PD-L1 expression. However, significant toxicity was noted with ipilimumab and nivolumab, with 46% of patients experiencing grade 3--4 toxicity. Even though the results with immunotherapy are promising for sRCC compared with historical data, a majority of patients do not respond and progression is inevitable, thus development of novel treatment strategies is urgently needed.

###### 

Summary of studies for sarcomatoid renal cell cancer

  Author                          N     Treatment                                                Objective response (%)   PFS (months)   OS (months)
  ------------------------------- ----- -------------------------------------------------------- ------------------------ -------------- -------------
  Sella *et al* [@R26]            8     Cyclophosphamide+vincristine + doxorubicin+dacarbazine   25                       NA             13
  Mian *et al* [@R27]             67    Interferon based therapy                                 21                       NA             19
  Escudier *et al* [@R28]         23    Doxorubicin+ifosfamide                                   0                        2.2            3.3
  Haas *et al* [@R4]              38    Gemcitabine+doxorubicin                                  15.8                     3.5            8.8
  Golshayan *et al* [@R29]        26    Sunitinib                                                19                       5.3            11.8
  Kyriakopoulous *et al* [@R30]   230   VEGF inhibitors                                          21                       4.5            10.4
  Mckay *et al* [@R10]            16    Atezolizumab+bevacizumab                                 44                       NA             NA
  McDermott *et al* [@R11]        60    Ipilimumab+nivolumab                                     56.7                     8.4            31.2

N, number of patients in the study; NA, not reported; OS, overall survival; PFS, progression-free survival; VEGF, vascular endothelial growth factor.

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and PD-1 are inhibitory receptors on T cells that limit T cell activation and function. These proteins act through distinct mechanisms to block T cell activation. CTLA-4 is expressed after initial T cell activation and acts to sequester ligands B7-1 and B7-2 (CD80, CD86) that are required for signaling through the costimulatory receptor CD28.[@R18] Blockade of CTLA-4 results in enhanced activation of primary T cells and clonal expansion of nascent CD8+T cell clones.[@R18] Anti-CTLA4 antibodies with heavy chains capable of fixing complement may also eliminate inhibitory T cell subsets, such as regulatory foxP3+CD4+T cells, from the tumor microenvironment.[@R19] In contrast, therapies targeting the PD-1/PD-L1 axis act on CD8+T cells that have undergone initial activation but acquired functional attenuation due to chronic exposure to antigen through a process termed T cell exhaustion.[@R20] Thus, although the two therapeutic strategies both fall under the purview of immune checkpoint inhibition, they act through distinct mechanisms to selectively potentiate activation of naïve (anti-CTLA-4) or exhausted (anti-PD-1/PD-L1) CD8+T cells. A possible explanation for the secondary responsiveness to ipilimumab observed in this patient is that progression of RCC results in development of neoantigens that can be recognized by naïve T cells in a manner facilitated by anti-CTLA-4.

The use of ipilimumab is limited to four doses when given in combination with nivolumab given concerns for significant autoimmune toxicities.[@R21] Checkmate 016 evaluated the role of intravenous nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (N3I1), nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (N1I3) or nivolumab 3 mg/kg plus ipilimumab 3 mg/kg (N3I3) every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks until progression or toxicity in RCC patients.[@R22] The incidence of grade 3/4 AE was significant with N1I3 and N3I3 dosing and hence the regimen used in our patients is FDA approved.

The use of ipilimumab with nivolumab a salvage therapy has been reported in patients with melanoma, with approximately 50% of patients demonstrating disease control.[@R23] Unfortunately, 68% of these patients experienced clinically significant toxicity resulting in 40% of patients discontinuing therapy.

Salvage ipilimumab and nivolumab has been found to be safe and effective in immune checkpoint inhibitors (ICI) refractory melanoma and ccRCC patients.[@R23] The TITAN trial that was discussed at European Society of Medical Oncology (ESMO) 2019 evaluated the role of salvage ipilimumab in combination with nivolumab for patients with stable disease/progressive disease on single agent nivolumab and noted a 10 per cent salvage rate with ipilimumab. This study is different from our approach as our patient had received prior ipilimumab and nivolumab, salvage ipilimumab was added when the patient had progressed on single agent nivolumab. In the TITAN trial, none of the patients had gotten upfront ipilimumab. In the TITAN trial, the CR rate was also significantly lower than checkmate 214 and with immature OS data, suggesting that upfront ipilimumab may be warranted for eligible patients. Another retrospective study evaluated the use of ipilimumab and nivolumab as salvage therapy in patients with clear cell mRCC refractory to immunotherapy therapy combinations and a 40% partial response rate was noted.[@R24] It would also be worth further exploring the role of Ipilimumab with a dose of 3 mg/kg as salvage therapy if toxicity permits. Further studies are needed to determine which sRCC patients are appropriate for salvage ipilimumab with progression on nivolumab monotherapy. It is also unknown as to whether BAP1 loss in RCC defines a cohort that is immune responsive. Further, the optimal frequency and dose of ipilimumab treatment needs to be established.

Here, we report the first case of reinvigoration of responses in an sRCC patient undergoing nivolumab maintenance monotherapy with the addition of ipilimumab. This suggests that ipilimumab could be used to salvage maintenance nivolumab in sRCC and indicates that enhancing activation of naïve T cell subsets could be an important mechanism to engage effective immune responses in sRCC. Further studies are needed to evaluate this approach.
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